An Updated Interim Analysis of the Air Trial; an Open-label, Single-arm, 36-week, Phase 2 Trial of an Angiotensin Type 2 Receptor Agonist, C21, in Individuals With IPF
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要